SPTX (SPTX) Stock Price & Analysis
SPTX (SPTX) rose 9.01% to USD 17.66 as of June 10, 2026 at 10:59 UTC, according to Nexqual real-time market data.
SPTX last closed at USD 16.2; the session ranged USD 16–18.34 on volume of 148,181 shares. Market capitalization is $945.35M, with a 52-week range of USD 14.85–23 (NMS). Source: Nexqual, June 10, 2026 at 10:59 UTC.
Key Statistics (as of June 10, 2026 at 10:59 UTC)
| Price | USD 17.66 |
|---|---|
| Change | ▲ 9.01% (up) |
| Previous Close | USD 16.2 |
| Open | USD 16 |
| Day Range | USD 16 – 18.34 |
| 52-Week Range | USD 14.85 – 23 |
| Volume | 148,181 shares |
| Market Cap | $945.35M |
| Exchange | NMS |
Technical Analysis (SPTX)
Nexqual's technical model rates SPTX "NEUTRAL" based on 2 bullish and 2 bearish signals across 26 daily candles, as of June 10, 2026 at 10:59 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 36.48 (neutral) |
| MACD | 0.22 (positive) |
Analyst Ratings (SPTX)
Wall Street analysts rate SPTX "Strong Buy" based on 4 analysts, with a mean price target of USD 35 (range USD 30–40), per Nexqual as of June 10, 2026 at 10:59 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 35 |
| High Target | USD 40 |
| Low Target | USD 30 |
| Buy / Hold / Sell | 4 / 0 / 0 |
Earnings (SPTX)
| EPS Estimate | USD -0.6 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -10.34 vs est -3.88 ▼ miss |
Source: Nexqual, June 10, 2026 at 10:59 UTC.
Financials & Fundamentals (SPTX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -28.08% |
| Current Ratio | 17.46 |
| Free Cash Flow | $-50.78M |
Source: Nexqual, June 10, 2026 at 10:59 UTC.
Financial Health Score (SPTX)
Nexqual rates SPTX's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 10:59 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — No data |
| Cash Flow | Weak — Operating cash flow -$78M |
| Efficiency | Critical — ROE -28%, ROA -18.9% |
Ownership (SPTX)
| Insider Ownership | +35.06% |
|---|---|
| Institutional Ownership | +28.37% |
| Shares Outstanding | 53.53M |
| Float | 2.89M |
| Short % of Float | +3.47% |
Source: Nexqual, June 10, 2026 at 10:59 UTC.
Leadership (SPTX)
SPTX is led by Daphne Zohar (age 54), Founder, CEO, President & Director, per Nexqual as of June 10, 2026 at 10:59 UTC.
| Founder, CEO, President & Director | Daphne Zohar (age 54) |
|---|---|
| Co-Founder & Chief Scientific Officer | Michael Cunyuan Chen (age 41) |
| Chief Medical Officer & President of Clinical Development | Antony Loebel (age 64) |
| Chief Financial Officer | Lauren A. White (age 46) |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| COAG | Hemab Therapeutics Holdings, In | USD 27 | ▲ 6.72% |
| KLRA | Kailera Therapeutics, Inc. | USD 19.64 | ▲ 1.39% |
| AVLN | Avalyn Pharma Inc. | USD 28.67 | ▲ 5.95% |
| ODTX | Odyssey Therapeutics, Inc. | USD 17.09 | ▲ 4.02% |
| EIKN | Eikon Therapeutics, Inc. | USD 8.77 | ▼ 2.12% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 10:59 UTC. This page is informational and not investment advice.